Low Dose Nivolumab With Chemotherapy vs Standard Chemotherapy as First-Line Treatment in Advanced or Metastatic NSCLC

This is a multicenter, two-arm randomized, parallel group design trial to evaluate superiority and safety of low dose Nivolumab (40mg) combined with standard chemotherapy versus standard chemotherapy alone in patients with non-small cell lung cancer.

Trial Details

NCT ID
NCT07050043
Phase
PHASE3
Sponsor
Dr Arvindran A/L Alaga
Status
RECRUITING
Cancer Type
Lung Cancer
Interventions
  • Nivolumab 40mg
  • Cisplatin, Carboplatin, Pemetrexed, Gemcitabine, Paclitaxel, Docetaxel
Locations (sample)
  • Alor Star, Kedah, Malaysia|6.12104,100.36014

Key Eligibility Criteria

  • Male/female participants who are at least 18 years of age on the day of signing informed consent.
  • Histologically confirmed, treatment naïve, locally advanced, or metastatic (stage IIIB - IV (per AJCC version 8), squamous or non-squamous NSCLC wi…
  • Patients must be treatment naïve with respect to locally advanced or metastatic disease. Patients who received prior treatment with curative intent…
  • Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. Evaluation of ECOG is to be performed within 7 days prior to the fi…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lung Cancer Trials on Trialify →